CEPH, PWRM, PennyOmega.com Stock Report! Cephalon Inc. and Power 3 Medical Products Inc.
PennyOmega.com Hot Stock News & Alerts!
________________________________________
FREE Daily Stock Alerts From PennyOmega.com
________________________________________
Friday November 13, 2009
PennyOmega.com Stock Report!
CEPH, PWRM
**************************************************************
CEPH, Cephalon Inc.
CEPH engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.
According to a Securities and Exchange Commission filing yesterday, CEPH will give Barr Pharmaceuticals Inc. (which now is part of Israel-based Teva Pharmaceutical Industries) a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement.
More about CEPH at www.cephalon.com
**************************************************************
PWRM, Power 3 Medical Products Inc, PWRM.OB
PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. PWRM operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.
PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009
Further international recognition of validity as the PWRM’s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”
More about PWRM at www.power3medical.com
***********Advertisement***********
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
Tags: Alzheimer disease, breast cancer, cancer disease, central nervous system, CEPH, Cephalon Inc, inflammatory disease, oncology therapeutic, pain, Parkinson disease, Power 3 Medical Products, protein regulation, PWRM, PWRM.OB
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
